FilingSEC EDGAR8-K
Caribou Biosciences Announces Discontinuation of CAR-T Programs and Restructuring
· SEC accepted
StageRestructuring
Filing content
Due to a challenging financing environment, the company is discontinuing its CAR-T therapy programs and implementing a workforce reduction.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…